$695 | Single User
$1395 | Global License

Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Oct 2013 | 75 | In Stock

Introduction

Scope


The prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medivation and Astellas expected to seek approval for their androgen receptor antagonist Xtandi (enzalutamide) for the treatment of castrate-resistant prostate cancer (CRPC) patients in the pre-chemotherapy setting.



Johnson & Johnson's Zytiga (abiraterone) – which was approved for pre-chemotherapy usage in December last year – has demonstrated that a notable commercial opportunity exists for treatment of prostate cancer at this stage. Indeed, some analysts believe that the pre-chemotherapy market could be worth up to billion in the US alone.



Furthermore, initial key opinion leader (KOL) feedback in response to top-line data from Medivation's PREVAIL study – which was released last week – would appear to suggest that Xtandi may emerge as the therapy of choice in pre-chemotherapy patients. See In Focus – Will PREVAIL data allow Medivation's Xtandi to overtake Johnson & Johnson's Zytiga in the pre-chemotherapy prostate cancer market?



Approval for the treatment of pre-chemotherapy patients is expected to significantly increase the use of Xtandi among urologists (in addition to oncologists). This population of physicians will be keen to use Xtandi, not only given its impressive overall survival (OS) and disease progression data, note KOLs, but its greater convenience; such as the lack of requirement to dose with steroids.



In addition, Xtandi's status as an androgen receptor antagonist (a familiar drug class among urologists) may prove to be useful in driving longer-term use in even earlier lines of therapy – a strategy that Johnson & Johnson is also pursuing for their next-generation prostate cancer treatment ARN-509, which was acquired from Aragon Pharmaceuticals earlier this year for a cost of up to billion.


Puchase Reasons


This week's Physician Views poll will look to assess whether initial KOL and analyst reaction to the top-line PREVAIL data is shared by the broader urologist and oncologist populations. FirstWord is polling urologists and oncologists based in both the US and EU5 with the following questions:


  • What percentage of castrate-resistant prostate cancer patients do you currently treat in the pre-chemotherapy setting with abiraterone (Zytiga)?

  • Based on top-line data from the PREVAIL study, and assuming enzalutamide (Xtandi) is approved for the treatment of castrate-resistant prostate cancer in the pre-chemotherapy setting, to what percentage of new pre-chemotherapy patients would you prescribe the drug once approved?

  • Based on data from the PREVAIL study, to what percentage of new pre-chemotherapy patients do you expect to prescribe enzalutamide (Xtandi) to on an off-label basis prior to approval?

  • What characteristic would most influence you to prescribe enzalutamide (Xtandi) in favour of abiraterone (Zytiga) in the pre-chemotherapy setting?

  • Based on enzalutamide's mechanism of action (androgen receptor antagonist), how comfortable would you be in prescribing the drug on an off-label basis in the hormone ablation setting?
  • Table of Contents
    for Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    75 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • 360i Research
    • 99Strategy
    • Allied Market Research
    • Asia Market Information & Development Co.
    • Azoth Analytics
    • BioInformant
    • Bizwit Research and Consulting
    • Black Swan Analysis
    • Canadean
    • CBR Pharma Insights
    • CRI
    • Current Analysis
    • Current Partnering
    • Daedal Research
    • Data bridge
    • Delve Insight
    • DPI Research
    • FirstWord Pharma
    • Future Market Insights
    • GBI Research
    • Global Data
    • Global Markets Direct
    • Global Research and Data Services GRDS
    • GMR Data
    • HeyReport
    • HongChun
    • HTStec
    • ICD Research
    • iGATE Research
    • IMARC
    • Industry ARC
    • Inkwood Research
    • IQ4I
    • Jain PharmaBiotech
    • Kelly Scientific
    • La Merie
    • Lifescience Intellipedia
    • LP Information
    • Market Data Forecast
    • Market Research Future
    • Marketline
    • MarketsandMarkets
    • McDerson
    • MedMarket Diligence
    • Meticulous Research
    • MicroMarketMonitor
    • MIReports
    • Mordor Intelligence LLC
    • MP Advisors
    • Occams Business Research
    • Prof Research
    • Progressive Markets
    • ProGrow Pharma Partners
    • Renub
    • Research Impact
    • RNCOS
    • Rockville Research
    • S&P Consulting
    • StratisticsMRC
    • The Business Research Company
    • Triton Market Research
    • Venture Planning Group (VPG)
    • VPA Research